The first stock you ever buy could be the most important. These three names won't disappoint.
News & Analysis: Pfizer
Xeljanz recently ran into a safety problem, but investors aren't sure if this will open doors for similar drugs in development, or slam them shut.
One of these is paying a more generous dividend, but is it right for your portfolio?
A drug that disappointed in 2018 will get an unexpected dance at the big ball.
After a great 2018, what's in store for Pfizer in 2019 and the next two years?
Putting an end to drug rebates to insurers could kick-start the use of low-cost biosimilar medications.
The Trump administration has unveiled a plan to deliver on his campaign promise to take on big pharmaceutical companies.
Here's why some of the industry's largest players are telling investors not to expect any fireworks this year.
Israeli scientists claim they have a cure for cancer. Investors' response? The proof is in the pudding.
PFE earnings call for the period ending December 31, 2018.